Stephen A Strugnell Selected Research

Secondary Hyperparathyroidism

1/2022	Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism.
1/2019	Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
1/2017	Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease.
1/2016	Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.
1/2011	Differential effects of oral doxercalciferol (Hectorol) or paricalcitol (Zemplar) in the Cyp27b1-null mouse model of uremia.
10/2010	Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis.
3/2006	The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells.
10/2004	Tissue distribution and activity studies of 1,24-dihydroxyvitamin D2, a metabolite of vitamin D2 with low calcemic activity in vivo.
9/2004	Effects of vitamin D compounds on renal and intestinal Ca2+ transport proteins in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen A Strugnell Research Topics

Disease

9	Secondary Hyperparathyroidism 01/2022 - 09/2004
7	Neoplasms (Cancer) 01/2005 - 01/2002
4	Chronic Renal Insufficiency 01/2022 - 01/2016
4	Retinoblastoma (Glioblastoma, Retinal) 09/2004 - 01/2002
3	Body Weight (Weight, Body) 01/2022 - 01/2005
3	Hypercalcemia (Milk Alkali Syndrome) 01/2017 - 09/2004
3	Renal Insufficiency (Renal Failure) 01/2011 - 09/2004
3	Weight Loss (Weight Reduction) 09/2004 - 01/2002
1	Obesity 01/2022
1	Overweight 01/2022
1	Hyperphosphatemia 01/2017
1	Kidney Diseases (Kidney Disease) 01/2011
1	Uremia 01/2011
1	Osteitis 01/2011
1	Hypocalcemia 10/2010
1	Hypophosphatemia 10/2010
1	Hypercalciuria 10/2010
1	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2006
1	Breast Neoplasms (Breast Cancer) 01/2005
1	Bone Resorption 10/2004
1	Melanoma (Melanoma, Malignant) 09/2004

Drug/Important Bio-Agent (IBA)

15	Vitamin D FDA LinkGeneric 01/2022 - 01/2002
6	CalciumIBA 10/2010 - 01/2002
4	Pharmaceutical PreparationsIBA 09/2004 - 01/2002
3	Ergocalciferols (Ergocalciferol)FDA LinkGeneric 01/2022 - 05/2002
3	Calcifediol (Calcidiol)FDA Link 01/2022 - 01/2016
3	1 alpha-hydroxyergocalciferol (doxercalciferol)FDA Link 01/2011 - 05/2002
2	Cholecalciferol (Vitamin D3)FDA Link 01/2022 - 09/2004
2	25-hydroxyvitamin DIBA 01/2022 - 01/2019
2	Calcitriol Receptors (Calcitriol Receptor)IBA 01/2017 - 01/2005
2	Calcitriol (Calcijex)FDA LinkGeneric 01/2011 - 05/2002
2	hydroxide ionIBA 01/2005 - 10/2004
1	paricalcitol (Zemplar)FDA Link 01/2011
1	Phosphorus (Red Phosphorus)IBA 10/2010
1	Cinacalcet (Sensipar)FDA Link 10/2010
1	Dietary CalciumIBA 10/2010
1	Lactose FDA LinkGeneric 10/2010
1	Parathyroid Hormone (Parathormone)IBA 10/2010
1	Vitamin D3 24-HydroxylaseIBA 02/2006
1	ProdrugsIBA 02/2006
1	1,24-dihydroxyvitamin D2IBA 01/2005
1	1,25-dihydroxyvitamin DIBA 10/2004
1	SilverIBA 09/2004
1	Monophenol Monooxygenase (Tyrosinase)IBA 09/2004
1	Tumor Viral Antigens (Large T Antigen)IBA 09/2004
1	beta Subunit Luteinizing HormoneIBA 01/2002

Therapy/Procedure

1	Nephrectomy 01/2011
1	Topical Administration 02/2006
1	Therapeutics 10/2004